Italy updates marketing authorization for apixaban medicine Apixaban Viatris Pharma
Italy's medicines agency AIFA has published an official notice in the Gazzetta Ufficiale about a change to the marketing permission for 'Apixaban Viatris Pharma', a human medicine based on apixaban. The notice appeared in Serie Generale no. 254 on 31 October 2026. The excerpt provided does not list what exactly was changed.
This summary was generated by AI; the official source prevails.
What does it mean?
This is an official Italian notice that the permission to sell a blood-thinning medicine called apixaban under the name 'Apixaban Viatris Pharma' has been changed. The notice itself does not say what the change is, so anyone who uses this medicine would need to check with a pharmacist or doctor.
Who is affected?
Patients who take or may take the apixaban medicine 'Apixaban Viatris Pharma' and the people who prescribe or sell it.